Dr. Brannigan on genetic evaluation of the infertile male

here was a higher concordance of somatic alterations between tissue and ctDNA testing in patients with metastases vs those without.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

This announcement follows an earlier FDA decision to grant approval to the company’s tissue-based comprehensive genomic profiling test FoundationOne CDx for the same therapy and indication in August 2023.

“Gay people have had this history of feeling like the health care system and the structures that are supposed to protect them haven't protected them and kept them safe,” says Channa Amarasekera, MD.

"This information, and future expansions of this work could help refine the ways in which key clinical decisions are made..." says Michael S. Leapman, MD, MHS.

“Even when we adjusted for other clinical variables, like age or grade of tumor, this signature was still independently associated with recurrence after treatment for this form of kidney cancer," says Simpa S. Salami, MD, MPH.